Exposure to innovative and transformative biotechnology companies has been a part of Pinnacle’s SMID investment strategy since our portfolio’s inception in 1996. Without a doubt, some of our most successful investments have come from this industry. Surprisingly, we have learned over the years that most investment managers avoid biotech stocks due to the inherent binary risks that come with drug development. We wanted to discuss why we think that the opportunity set is constructive.